Ground News

News from CureDuchenne

Stay current with all the latest and breaking news from CureDuchenne. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 18 have been published by CureDuchenne which Ground News has aggregated in the past 3 months.

Ground News rates CureDuchenne’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to CureDuchenne. You can read more about how we’ve determined CureDuchenne’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about CureDuchenne

Where is CureDuchenne located?CureDuchenne's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top CureDuchenne News

FDA · United States

FDA Meeting Gives Window Into Gene Therapy Field’s Angst

100% Center coverage: 2 sources

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a regulatory forum Thursday.See the Story

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

100% Left coverage: 1 sources

RGX-202 demonstrating consistent evidence of positively changing disease trajectory for DuchenneAll dose level 2 participants exceeded external natural history controls on all functional measuresBiomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated agesOne new participant aged…See the Story

Satellos’ DMD treatment shows efficacy signals in adult patients

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.The post Satellos’ DMD treatment shows efficacy signals in adult patients appeared first on Clinical Trials Arena.Irvine, California · Irvine See the Story

CureDuchenne Ventures Invests in Entos Pharmaceuticals

Entos Pharmaceuticals, an Edmonton, Canada-based biotech company that develops genetic medicines, received an investment from CureDuchenne Ventures. The amount of the deal was not disclosed. The company intends to use the funds to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD). Led by CEO John Lewis, Entos […] The post CureDuchenne Ventures Invests in Entos Pharmace…Technology · Newport Beach See the Story

CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor to Advance Research and Improve Care for Individuals with Duchenne and Becker

100% Center coverage: 3 sources

Newport Beach, Calif., May 21, 2025 — CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, proudly announces the appointment of Brenda Wong, MD, as its new Chief Medical Advisor, effective January 5, 2026. A nationally recognized authority in neuromuscular medicine and clinical research, Dr. Wong has devoted her career to compassionate, patient-centered care for those living with Duchenne and …Maryland · Maryland See the Story

Entrada receives authorization to start exon 44 skipping trial in Europe

CureDuchenne provided early funding to Entrada Therapeutics. Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to skipping exon 44. The study, which will run in the UK and the EU, will start in the 2nd quarter of 2025. Entrada is also planning a Phase 1/2 for ambulatory individuals with Duchenne amenable to skipping exon 45, which will…United Kingdom · United Kingdom Read Article

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

100% Center coverage: 2 sources

By Siddhi MahatoleFDA See the Story

CureDuchenne Raises More than $1M at Napa in Miami to Help Find a Cure for Duchenne Muscular Dystrophy

Premier Wine Tasting and Auction Brought Acclaimed Napa Valley Vintners Together with Miami Philanthropists to Benefit Global Nonprofit CureDuchenneMIAMI, FL, April 16, 2025 – CureDuchenne, a global nonprofit committed to finding a cure for Duchenne muscular dystrophy, and Event Chair Susan Finazzo hosted the fourth annual “Napa in Miami” Wine Tasting and Auction on April 5, 2025 at Mandarin Oriental, Miami. The premier wine event brought a coll…New York State · New York Read Article

Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study

Wave Life Science Exon Skipping in DuchenneWave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s exon skipping investigational therapy for Duchenne being investigated for individuals who are amenable to exon 53 skipping. We will share the recently announced 48-week FORWARD-53 data.Watch the webinar HEREThe post Wave Life Sciences: Update on 48-week Data fro…Read Article

A Taste of Napa

Napa in Miami 2025 Auction CatalogBid by proxy by emailing okairy@cureduchenne.orgThe post A Taste of Napa appeared first on CureDuchenne.Miami, Florida · Miami Read Article

News from CureDuchenne

News from CureDuchenne

Information about CureDuchenne

Media Bias Ratings

Factuality

Ownership

Top CureDuchenne News

FDA Meeting Gives Window Into Gene Therapy Field’s Angst

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Satellos’ DMD treatment shows efficacy signals in adult patients

CureDuchenne Ventures Invests in Entos Pharmaceuticals

CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor to Advance Research and Improve Care for Individuals with Duchenne and Becker

Entrada receives authorization to start exon 44 skipping trial in Europe

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

CureDuchenne Raises More than $1M at Napa in Miami to Help Find a Cure for Duchenne Muscular Dystrophy

Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study

A Taste of Napa

Similar News Topics

Topics Most Covered by CureDuchenne

Sources Covering Similar Topics

Breaking News Topics Related to CureDuchenne